Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the Treatment of Autoimmune Diseases at FOCIS 2013 FOCIS 2013 Business Wire CAMBRIDGE, Mass. -- June 21, 2013 Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will present positive Phase 1 trial results on IMO-8400, a selective inhibitor of Toll-like receptors (TLRs) 7, 8 and 9 and a lead candidate for the treatment of autoimmune diseases, at the 13^th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), June 27-30, 2013, in Boston, MA. Details of the presentation are as follows: Date: Saturday, June 29, 2013 Time: 6:30-7:45pm ET Location: Commonwealth Hall, The Boston Seaport Hotel Abstract Number: S.85 Title: Phase 1 clinical trial of IMO-8400, an antagonist of Toll-like receptors 7, 8 and 9 About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has a clinical development program in autoimmune diseases. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. For more information, visit http://www.iderapharma.com. Contact: Idera Pharmaceuticals, Inc. Lou Arcudi, 617-679-5517 email@example.com
Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the Treatment of Autoimmune
Press spacebar to pause and continue. Press esc to stop.